📰 Refractory Diffuse Largeb Cell News
Refractory Diffuse Largeb Cell News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Refractory Diffuse Largeb Cell. Real-time updates on events, politics, business and more.
April 19, 2024
Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.
November 2, 2023
Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include...
November 2, 2023
Presentations to highlight clinical utility of ZYNLONTA® as a single agent and in combination Oral presentation to include initial results of investigator-initiated Phase 2 study evaluating...
November 2, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting 02.11.2023 / 14:05 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, Novemb...
July 11, 2023
Basel, 11 July 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has granted conditional marketing authorisation for…
May 11, 2023
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39... | May 11, 2023
May 11, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 M...
April 26, 2023
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase
April 26, 2023
Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
January 6, 2023
Investegate announcements from F. Hoffmann-La Roche Ltd, FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma